JavaScript NENÍ povolen !

Článek

FT
Medvik - BMČ

Je něco špatně v tomto záznamu ?

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

SS. Anand, J. Bosch, JW. Eikelboom, SJ. Connolly, R. Diaz, P. Widimsky, V. Aboyans, M. Alings, AK. Kakkar, K. Keltai, AP. Maggioni, BS. Lewis, S. Störk, J. Zhu, P. Lopez-Jaramillo, M. O'Donnell, PJ. Commerford, D. Vinereanu, N. Pogosova, L....

Lancet. 2018 ; 391 (10117) : 219-229. [pub] 20171110

ISSN 1474-547X
Medvik
Zdroj

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz https://www.medvik.cz/link/bmc19001096

Online Plný text

NLK ProQuest Central od 1992-01-04 do Před 3 měsíci
Nursing & Allied Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health & Medicine (ProQuest) od 1992-01-04 do Před 3 měsíci
Family Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Psychology Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Health Management Database (ProQuest) od 1992-01-04 do Před 3 měsíci
Public Health Database (ProQuest) od 1992-01-04 do Před 3 měsíci

PubMed 29132880
DOI 10.1016/s0140-6736(17)32409-1
Knihovny.cz E-zdroje

BACKGROUND: Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. METHODS: This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants. FINDINGS: Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043). INTERPRETATION: Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding. FUNDING: Bayer AG.

3rd Department of Internal Medicine Semmelweis University Budapest Hungary

Amphia Ziekenhuis and Werkgroep Cardiologische centra Nederland Utrecht Netherlands

ANMCO Research Center Florence Italy

Bayer AG Leverkusen Germany

Bayer AG Whippany NJ USA

Brigham and Women's Hospital Heart and Vascular Center Harvard Medical School Boston MA USA

Cardiocenter University Hospital Kralovske Vinohrady and 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Centre for Cardiovascular Science University of Edinburgh Edinburgh UK

Comprehensive Heart Failure Center University Hospital at University of Würzburg Würzburg Germany

Dante Pazzanese Institute of Cardiology and University Santo Amaro São Paulo Brazil

Department of Cardiovascular Sciences University of Leuven Leuven Belgium

Department of Epidemiology and Preventive Medicine Monash University Melbourne VIC Australia

Department of Medicine K2 Karolinska Institute Stockholm Sweden

Department of Medicine McMaster University Hamilton ON Canada

Department of Medicine University of Washington Seattle WA USA

Dupuytren University Hospital Limoges France

Estudios Clínicos Latino America and Instituto Cardiovascular de Rosario Rosario Argentina

FuWai Hospital Beijing China

Lady Davis Carmel Medical Centre and the Ruth and Bruce Rappaport School of Medicine Technion IIT Haifa Israel

National Research Centre for Preventative Medicine Moscow Russia

National University of Ireland Galway Ireland

Population Health Research Institute McMaster University and Hamilton Health Sciences Hamilton ON Canada

Research Institute FOSCAL Bucaramanga Bucaramanga Colombia

School of Rehabilitation Sciences McMaster University Hamilton ON Canada

Thrombosis Research Institute and University College London London UK

University of Cape Town Cape Town South Africa

University of Medicine and Pharmacy Carol Davila University and Emergency Hospital Bucharest Romania

Citace poskytuje Crossref.org

000: 00000naa a2200000 a 4500

001: bmc19001096

003: CZ-PrNML

005: 20190108130203.0

007: ta

008: 190107s2018 enk f 000 0|eng||

009: AR

024 7_: $a 10.1016/S0140-6736(17)32409-1 $2 doi

035 __: $a (PubMed)29132880

040 __: $a ABA008 $b cze $d ABA008 $e AACR2

041 0_: $a eng

044 __: $a enk

100 1_: $a Anand, Sonia S $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada. Electronic address: anands@mcmaster.ca.

245 10: $a Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial / $c SS. Anand, J. Bosch, JW. Eikelboom, SJ. Connolly, R. Diaz, P. Widimsky, V. Aboyans, M. Alings, AK. Kakkar, K. Keltai, AP. Maggioni, BS. Lewis, S. Störk, J. Zhu, P. Lopez-Jaramillo, M. O'Donnell, PJ. Commerford, D. Vinereanu, N. Pogosova, L. Ryden, KAA. Fox, DL. Bhatt, F. Misselwitz, JD. Varigos, T. Vanassche, AA. Avezum, E. Chen, K. Branch, DP. Leong, SI. Bangdiwala, RG. Hart, S. Yusuf, . ,

520 9_: $a BACKGROUND: Patients with peripheral artery disease have an increased risk of cardiovascular morbidity and mortality. Antiplatelet agents are widely used to reduce these complications. METHODS: This was a multicentre, double-blind, randomised placebo-controlled trial for which patients were recruited at 602 hospitals, clinics, or community practices from 33 countries across six continents. Eligible patients had a history of peripheral artery disease of the lower extremities (previous peripheral bypass surgery or angioplasty, limb or foot amputation, intermittent claudication with objective evidence of peripheral artery disease), of the carotid arteries (previous carotid artery revascularisation or asymptomatic carotid artery stenosis of at least 50%), or coronary artery disease with an ankle-brachial index of less than 0·90. After a 30-day run-in period, patients were randomly assigned (1:1:1) to receive oral rivaroxaban (2·5 mg twice a day) plus aspirin (100 mg once a day), rivaroxaban twice a day (5 mg with aspirin placebo once a day), or to aspirin once a day (100 mg and rivaroxaban placebo twice a day). Randomisation was computer generated. Each treatment group was double dummy, and the patient, investigators, and central study staff were masked to treatment allocation. The primary outcome was cardiovascular death, myocardial infarction or stroke; the primary peripheral artery disease outcome was major adverse limb events including major amputation. This trial is registered with ClinicalTrials.gov, number NCT01776424, and is closed to new participants. FINDINGS: Between March 12, 2013, and May 10, 2016, we enrolled 7470 patients with peripheral artery disease from 558 centres. The combination of rivaroxaban plus aspirin compared with aspirin alone reduced the composite endpoint of cardiovascular death, myocardial infarction, or stroke (126 [5%] of 2492 vs 174 [7%] of 2504; hazard ratio [HR] 0·72, 95% CI 0·57-0·90, p=0·0047), and major adverse limb events including major amputation (32 [1%] vs 60 [2%]; HR 0·54 95% CI 0·35-0·82, p=0·0037). Rivaroxaban 5 mg twice a day compared with aspirin alone did not significantly reduce the composite endpoint (149 [6%] of 2474 vs 174 [7%] of 2504; HR 0·86, 95% CI 0·69-1·08, p=0·19), but reduced major adverse limb events including major amputation (40 [2%] vs 60 [2%]; HR 0·67, 95% CI 0·45-1·00, p=0·05). The median duration of treatment was 21 months. The use of the rivaroxaban plus aspirin combination increased major bleeding compared with the aspirin alone group (77 [3%] of 2492 vs 48 [2%] of 2504; HR 1·61, 95% CI 1·12-2·31, p=0·0089), which was mainly gastrointestinal. Similarly, major bleeding occurred in 79 (3%) of 2474 patients with rivaroxaban 5 mg, and in 48 (2%) of 2504 in the aspirin alone group (HR 1·68, 95% CI 1·17-2·40; p=0·0043). INTERPRETATION: Low-dose rivaroxaban taken twice a day plus aspirin once a day reduced major adverse cardiovascular and limb events when compared with aspirin alone. Although major bleeding was increased, fatal or critical organ bleeding was not. This combination therapy represents an important advance in the management of patients with peripheral artery disease. Rivaroxaban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone, but reduced major adverse limb events and increased major bleeding. FUNDING: Bayer AG.

650 _2: $a senioři $7 D000368

650 _2: $a amputace $x statistika a číselné údaje $7 D000671

650 _2: $a Aspirin $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D001241

650 _2: $a kardiovaskulární nemoci $x mortalita $x prevence a kontrola $7 D002318

650 _2: $a nemoci arterie carotis $x komplikace $x farmakoterapie $x epidemiologie $7 D002340

650 _2: $a vztah mezi dávkou a účinkem léčiva $7 D004305

650 _2: $a dvojitá slepá metoda $7 D004311

650 _2: $a rozvrh dávkování léků $7 D004334

650 _2: $a kombinovaná farmakoterapie $7 D004359

650 _2: $a inhibitory faktoru Xa $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D065427

650 _2: $a ženské pohlaví $7 D005260

650 _2: $a krvácení $x chemicky indukované $7 D006470

650 _2: $a lidé $7 D006801

650 _2: $a incidence $7 D015994

650 _2: $a dolní končetina $x krevní zásobení $x chirurgie $7 D035002

650 _2: $a mužské pohlaví $7 D008297

650 _2: $a lidé středního věku $7 D008875

650 _2: $a morbidita $7 D009017

650 _2: $a infarkt myokardu $x epidemiologie $x etiologie $x prevence a kontrola $7 D009203

650 _2: $a onemocnění periferních arterií $x komplikace $x farmakoterapie $x epidemiologie $7 D058729

650 _2: $a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D010975

650 _2: $a rivaroxaban $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000069552

650 _2: $a cévní mozková příhoda $x epidemiologie $x etiologie $x prevence a kontrola $7 D020521

655 _2: $a časopisecké články $7 D016428

655 _2: $a multicentrická studie $7 D016448

655 _2: $a randomizované kontrolované studie $7 D016449

655 _2: $a práce podpořená grantem $7 D013485

700 1_: $a Bosch, Jackie $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; School of Rehabilitation Sciences, McMaster University, Hamilton, ON, Canada.

700 1_: $a Eikelboom, John W $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.

700 1_: $a Connolly, Stuart J $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.

700 1_: $a Diaz, Rafael $u Estudios Clínicos Latino America and Instituto Cardiovascular de Rosario, Rosario, Argentina.

700 1_: $a Widimsky, Peter $u Cardiocenter, University Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University Prague, Prague, Czech Republic.

700 1_: $a Aboyans, Victor $u Dupuytren University Hospital, Limoges, France.

700 1_: $a Alings, Marco $u Amphia Ziekenhuis and Werkgroep Cardiologische centra Nederland, Utrecht, Netherlands.

700 1_: $a Kakkar, Ajay K $u Thrombosis Research Institute and University College London, London, UK.

700 1_: $a Keltai, Katalin $u 3rd Department of Internal Medicine. Semmelweis University, Budapest, Hungary.

700 1_: $a Maggioni, Aldo P $u ANMCO Research Center, Florence, Italy.

700 1_: $a Lewis, Basil S $u Lady Davis Carmel Medical Centre and the Ruth and Bruce Rappaport School of Medicine, Technion-IIT, Haifa, Israel.

700 1_: $a Störk, Stefan $u Comprehensive Heart Failure Center, University Hospital at University of Würzburg, Würzburg, Germany.

700 1_: $a Zhu, Jun $u FuWai Hospital, Beijing, China.

700 1_: $a Lopez-Jaramillo, Patricio $u Research Institute, FOSCAL-Bucaramanga, Bucaramanga, Colombia.

700 1_: $a O'Donnell, Martin $u National University of Ireland, Galway, Ireland.

700 1_: $a Commerford, Patrick J $u University of Cape Town, Cape Town, South Africa.

700 1_: $a Vinereanu, Dragos $u University of Medicine and Pharmacy Carol Davila, University and Emergency Hospital, Bucharest, Romania.

700 1_: $a Pogosova, Nana $u National Research Centre for Preventative Medicine, Moscow, Russia.

700 1_: $a Ryden, Lars $u Department of Medicine K2, Karolinska Institute, Stockholm, Sweden.

700 1_: $a Fox, Keith A A $u Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.

700 1_: $a Bhatt, Deepak L $u Brigham and Women's Hospital Heart and Vascular Center, Harvard Medical School, Boston, MA, USA.

700 1_: $a Misselwitz, Frank $u Bayer AG, Leverkusen, Germany.

700 1_: $a Varigos, John D $u Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia.

700 1_: $a Vanassche, Thomas $u Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.

700 1_: $a Avezum, Alvaro A $u Dante Pazzanese Institute of Cardiology & University Santo Amaro, São Paulo, Brazil.

700 1_: $a Chen, Edmond $u Bayer AG, Whippany, NJ, USA.

700 1_: $a Branch, Kelley $u Department of Medicine (Cardiology), University of Washington, Seattle, WA, USA.

700 1_: $a Leong, Darryl P $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.

700 1_: $a Bangdiwala, Shrikant I $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada.

700 1_: $a Hart, Robert G $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.

700 1_: $a Yusuf, Salim $u Population Health Research Institute, McMaster University and Hamilton Health Sciences, Hamilton, ON, Canada; Department of Medicine, McMaster University, Hamilton, ON, Canada.

700 1_: $a ,

773 0_: $w MED00010161 $t Lancet (London, England) $x 1474-547X $g Roč. 391, č. 10117 (2018), s. 219-229

856 41: $u https://pubmed.ncbi.nlm.nih.gov/29132880 $y Pubmed

910 __: $a ABA008 $b sig $c sign $y a $z 0

990 __: $a 20190107 $b ABA008

991 __: $a 20190108130404 $b ABA008

999 __: $a ok $b bmc $g 1365022 $s 1039219

BAS __: $a 3

BAS __: $a PreBMC

BMC __: $a 2018 $b 391 $c 10117 $d 219-229 $e 20171110 $i 1474-547X $m Lancet $n Lancet $x MED00010161

LZP __: $a Pubmed-20190107

Najít záznam

v PubMed

Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial

Najít záznam

Citační ukazatele

Možnosti archivace